Skip to content
Head to head

Supernus Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: SUPN · TAK

Updated moments ago

1-year performance, rebased to 100

SUPN -36.5%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
SUPNTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price28.6121.77
Change today+0.92%+1.68%
1-year return-36.1%+57.5%
Market cap$5.94B$69.76B
52-week range21.48 – 33.2213.92 – 22.07
Valuation
P/E (TTM)-37.64311.00
P/E percentile, own 5-yr range20th100th
P/B5.591.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.68-0.30
Net profit (TTM)$-141.25M$-970.94M
Revenue (TTM)$865.11M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+18.0%+6.7%
Gross margin87.6%65.8%
Operating margin3.2%14.3%
Net margin-5.1%0.9%
Free cash flow (TTM)$86.96M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership86.1%51.3%
Insider activity (12mo)20 buy / 26 sell19 buy / 31 sell
Short interest (% of float)7.9%0.1%
Analyst consensus83% buy / 17% hold (6)100% buy (1)
Analyst price target$53 (+84%)$50 (+132%)
StockVane view
StockVane Quant RatingE (11)C (90)
Company
Employees77847,029
Founded20051781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.